Cannabidiol in Opioid Use Disorder and Chronic Pain
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled cross-over human laboratory study with
a duration of approximately 3 weeks, during which participants will come to the testing site
for a total of five times: one initial screening session, and four experimental sessions
where study medication, Cannabidiol (CBD) will be administered, separated by at least 72
hours to limit carryover effects.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) VA Connecticut Healthcare System